Breast Cancer Diagnostics Market by Technique (Imaging, Molecular Testing, Tissue Biopsy Tests), Cancer Type (BRCA Breast Cancer, EGFR Mutation Test Breast Cancer, ER & PR Breast Cancer), Component, Diagnostic Type, End-User - Global Forecast 2024-2030

[192 Pages Report] The Breast Cancer Diagnostics Market size was estimated at USD 6.54 billion in 2023 and expected to reach USD 7.04 billion in 2024, at a CAGR 7.79% to reach USD 11.06 billion by 2030.

Breast cancer diagnostics refer to tests and procedures conducted to determine the stage of breast cancer, including blood tests, magnetic resonance imaging, Positron emission tomography (PET) scan, and computerized tomography (CT scan). Breast cancer diagnostics tests determine whether the cancer or tumor is restricted to the breast or has spread to other body organs such as lymph nodes. The changing lifestyles and dietary and nutrition regime has led to hormonal changes and caused an increase in the number of women diagnosed with breast cancer and necessitated the development of breast cancer diagnostic tests. Furthermore, government initiatives and incentives to raise awareness about breast cancer and female reproductive health have caused a surge in the number of cancer screening programs worldwide. However, the high costs associated with breast cancer screening tests, genetic testing, and cancer drugs prevent patients from availing the services for treatment and diagnosis of cancer. The lack of skilled personnel to initiate appropriate treatment diagnosis procedures poses significant challenges for cancer care. However, integrating machine learning (ML) and artificial intelligence (AI) in breast cancer diagnostic procedures has enabled early breast cancer diagnosis. AI algorithms can identify missed cancers and breast tissue features and help predict future cancers.

The American breast cancer diagnostics market is highly developed due to the notable prevalence of breast cancer and the presence of multiple advanced imaging techniques in the region. According to the American Cancer Society, approximately 287,850 new cases of invasive breast cancer were anticipated to be diagnosed in the United States in 2022, bolstering the need for breast cancer diagnosis. Additionally, the growing geriatric population, ongoing cancer-related research activities, and the rising burden of different types of breast cancer have enhanced the need for breast cancer diagnosis in Germany, New Zealand, the United Kingdom, and several other European nations. Moreover, the significant involvement of the European government in breast cancer detection and diagnosis programs has elevated the market scope. In the Asia-Pacific region, China and India are the most prevalent regions for the increasing cases of breast cancer patients, raising the need for breast cancer diagnostics. Furthermore, the emerging campaigns and breast cancer awareness programs have highlighted the need for breast cancer diagnostics in Asian countries.

The market dynamics represent an ever-changing landscape of the Breast Cancer Diagnostics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

• Market Drivers
  • Increasing incidence of breast cancer globally
  • Favorable reimbursement framework for breast cancer diagnosis
  • Growing number of breast cancer screening programs worldwide
• Market Restraints
  • High cost associated with breast cancer diagnostic tests
• Market Opportunities
  • Integration of artificial intelligence (AI) and machine learning (ML) in breast cancer diagnostic
  • Ongoing research and development activities in cancer diagnostic techniques
• Market Challenges
  • Dearth of the skilled and trained professionals

• Technique: Advancements in molecular and genomic biology advancing the penetration of molecular testing

  Imaging tests for breast cancer include mammography, ultrasound, and magnetic resonance imaging. Mammography refers to a procedure that utilizes X-ray images of the breast to detect symptoms and signs of the presence of breast tumors. Digital mammography is preferred over analog mammography as it can detect tumor presence with less radiation dosage and is used by physicians to enable early cancer detection. Ultrasound tests utilize sound waves to detect cancer and indicate whether a solid mass of tissues inside the breast is malignant or benign. Rapid advancements in molecular biology have facilitated molecular tests aimed at detecting cancer at the genomic level. Molecular testing procedures detect the presence of cancer biomarkers and genomic variations or mutations within a cancer patient’s genome to accurately determine the probability of cancer occurrence. These tests also enable patients with a family history of cancer to understand their chances of suffering from cancer.

• Cancer Type: BRCA breast cancer is highly implicated as a hereditary breast cancer

  The BRCA1 and BRCA2 genetic mutations are often implicated in breast cancer, and patients with the BRCA gene mutation are at a risk of suffering from breast cancer. The BRCA gene test and other BRCA testing methods determine if a patient's genome contains mutations that increase the risk of breast cancer. HER2 refers to a human protein called human epidermal growth factor receptor 2 (HER2) and is associated with a higher level of expression in breast cancer patients. HER2-positive breast cancer is cancer that gives a positive test result for the HER-2 protein. Immunohistochemistry tests determine the abundance of HER-2 proteins in phone breast cancer cells. HER2-positive cancers are associated with aggressive symptoms; however, they also respond better to breast cancer treatment regimes that target HER2 proteins specifically. Hormone receptor-positive or hormone-positive breast cancer cells have either estrogen (ER) or progesterone (PR) receptors or both. ER-positive or PR-positive tumors respond favorably to hormone therapy compared to ER-negative or PR-negative tumors. Physicians and medical professionals use these tests for effective medical decision-making.

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Breast Cancer Diagnostics Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Breast Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Breast Cancer Diagnostics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

• Solis Mammography Announces Acquisition of Carolina Breast Imaging

  Solis Mammography, a significant provider of specialized women's healthcare, announced its acquisition of Carolina Breast Imaging, a network of three breast imaging centers in eastern North Carolina. This acquisition aims to enhance patient care by offering advanced standards through fellowship-trained breast imaging specialists and state-of-the-art technology. [Published On: August 24, 2023]

• Johnson & Johnson Impact Ventures Invests in Mamotest to Improve Access to Care for Breast Cancer Patients in Latin America

  Johnson & Johnson Impact Ventures invested in Mamotest, signaling their commitment to supporting the company's growth and expansion efforts in Argentina, Mexico, and other countries within the region. Mamotest, an AI-based platform founded in 2012, is dedicated to making early diagnosis of breast cancer accessible to all, aiming to improve survival rates. [Published On: May 30, 2023]

• Sysmex Europe Distributes MammaTyper, an Advanced Breast Cancer Diagnostic Assay, Through The European Distribution Agreement With Cerca Biotech

  Sysmex Europe SE has established a distribution agreement with Cerca Biotech, spanning various markets in the EMEA region, including the UK, Ireland, and several European countries. This agreement aims to incorporate Cerca Biotech's innovative breast cancer diagnostic assay, MammaTyper, into Sysmex's Life Science portfolio. [Published On: April 24, 2023]

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Breast Cancer Diagnostics Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

The report delves into recent significant developments in the Breast Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 4D Path Inc., Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocept, Inc., Biodesix, Cardinal Health, Danaher Corporation, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fluxion Biosciences Inc. by Cell Microsystems, FUJIFILM Holdings Corporation, General Electric Company, Hologic, Inc., Illumina, Inc., Koninklijke Philips N.V., NanoString Technologies, Inc., NeoGenomics Laboratories, Olea Medical, OncoGenomX, Paragon Biosciences LLC by Catalent, Inc., Provista Diagnostics, Inc. by Todos Medical, Quest Diagnostics Incorporated, Siemens Healthcare Private Limited, and Thermo Fisher Scientific Inc..

This research report categorizes the Breast Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Technique
  • Imaging
    • Analog Mammography
    • Breast Ultrasound System
    • Digital Mammography
    • Mammography
    • MRI Scan
    • PET/CT Scan
  • Molecular Testing
  • Tissue Biopsy Tests
• Cancer Type
  • BRCA Breast Cancer
  • EGFR Mutation Test Breast Cancer
  • ER & PR Breast Cancer
  • HER 2 Breast Cancer
• Component
  • Consumables
    • Antibodies
    • Kits & Reagents
    • Probes
  • Instruments
    • Biopsy Instruments
    • Imaging Instruments
    • Pathology-Based Instruments
• Diagnostic Type
  • Ionizing Breast Imaging Technologies
  • Non-Ionizing Imaging Technologies
• End-User
  • Diagnostic Laboratories
  • Hospitals & Ambulatory Surgery Center
  • Research & Academic Institutes

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

1. What is the current market size and projected growth?
2. Which products, segments, applications, and regions offer promising investment opportunities?
3. What are the prevailing technology trends and regulatory frameworks?
4. What is the market share and positioning of the leading vendors?
5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?